120 related articles for article (PubMed ID: 20371737)
1. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine.
de Mey C; Mateva L; Krastev Z; Sachse R; Wood N; Malhotra B
J Clin Pharmacol; 2011 Mar; 51(3):397-405. PubMed ID: 20371737
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine.
Malhotra B; Gandelman K; Sachse R; Wood N
J Clin Pharmacol; 2009 Apr; 49(4):477-82. PubMed ID: 19246724
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.
Malhotra BK; Crownover PH; LaBadie R; Glue P; MacDiarmid SA
Eur J Clin Pharmacol; 2010 Feb; 66(2):171-6. PubMed ID: 19915829
[TBL] [Abstract][Full Text] [Related]
5. Influence of food on the pharmacokinetic profile of fesoterodine.
Malhotra B; Sachse R; Wood N
Int J Clin Pharmacol Ther; 2009 Jun; 47(6):384-90. PubMed ID: 19473600
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of fesoterodine.
Malhotra B; Guan Z; Wood N; Gandelman K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
8. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
10. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
[TBL] [Abstract][Full Text] [Related]
11. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.
Brynne N; Stahl MM; Hallén B; Edlund PO; Palmér L; Höglund P; Gabrielsson J
Int J Clin Pharmacol Ther; 1997 Jul; 35(7):287-95. PubMed ID: 9247842
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
Påhlman I; Kankaanranta S; Palmér L
Arzneimittelforschung; 2001 Feb; 51(2):134-44. PubMed ID: 11258043
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
[TBL] [Abstract][Full Text] [Related]
16. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.
Malhotra BK; Wood N; Sachse R
Int J Clin Pharmacol Ther; 2009 Sep; 47(9):570-8. PubMed ID: 19761716
[TBL] [Abstract][Full Text] [Related]
17. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.
Mock S; Dmochowski RR
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1659-66. PubMed ID: 24205892
[TBL] [Abstract][Full Text] [Related]
19. Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle.
Yoshida A; Fuchihata Y; Kuraoka S; Osano A; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
Urology; 2013 Apr; 81(4):920.e1-5. PubMed ID: 23497983
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.
Oishi M; Tomono Y; Yamagami H; Malhotra B
J Clin Pharmacol; 2014 Aug; 54(8):928-36. PubMed ID: 24619889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
